Pros and Cons of Regulations of Clinical Research

The regulation of clinical research has both pros and cons, based on the regulations provided by the regulatory body. This determines whether the regulation will be of benefit or if it will provide challenges for clinical research. In a bid to understand the why clinical research should be regulated, this paper will provide both the pros and cons of clinical research regulation.

Pros of Clinical Research

The main pros of regulating a clinical research is to provide maximum safety for those participating in the research, and to also allow for the transparency of the information gathered from the research (Cavalieri, Rupp, 2014). The research should be conducted in such a way that the participants are not put at any form of risk. There are many types of risks, and this may include contracting a disease from a victim or from the environment where the research is being conducted. The safety of the participants should not therefore be at stake. Secondly, the process of conducting the research, the methods of gathering used should also be transparent, thus making it easier to understand how the conclusion was reached (Olson, Claiborne, 2014).

Cons of Clinical Research

Regulation of clinical research might also lead to a lot of challenges, some of them being the following: poor room for conducting the research, and strict rules hindering proper research (Olson, Claiborne, 2014). The regulatory commission may not provide clear rules for conducting clinical research, a factor which might hinder the researches from conducting the clinical research at ease. Similarly, the rules might also be very strict, thus making it hard for the researchers to be able to conduct the research in the best way possible (Cavalieri, Rupp, 2014).

Reference

Cavalieri, R. J., Rupp, M. E., & Sigma Theta Tau International,. (2014). Business administration for clinical trials: Managing research, strategy, finance, regulation, and quality.

Olson, S., Claiborne, A. B., & Institute of Medicine (U.S.). (2012). Strengthening a workforce for innovative regulatory science in therapeutics development: Workshop summary. Washington, D.C: National Academies Press.